tetano
Editor, Senior Moderator
J Med Virol
. 2020 Jun 3.
doi: 10.1002/jmv.26102. Online ahead of print.
A Case of SARS-CoV-2 Infection in an Untreated HIV Patient in Tokyo, Japan
Takato Nakamoto[SUP] 1 [/SUP], Satoshi Kutsuna[SUP] 1 [/SUP], Yasuaki Yanagawa[SUP] 2 [/SUP], Kouhei Kanda[SUP] 1 [/SUP], Ayako Okuhama[SUP] 1 [/SUP], Yutaro Akiyama[SUP] 1 [/SUP], Yusuke Miyazato[SUP] 1 [/SUP], Satoshi Ide[SUP] 1 [/SUP], Keiji Nakamura[SUP] 1 [/SUP], Kei Yamamoto[SUP] 1 [/SUP], Norio Ohmagari[SUP] 1 [/SUP]
Affiliations
Abstract
We report a 28-year-old male co-infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; COVID-19) and human immunodeficiency virus (HIV). His clinical course of the COVID-19 pneumonia improved smoothly in 9 days; however, his immune status from HIV infection was not well-controlled due to a lack of antiretroviral therapy (ART). The HIV-1 viral load decreased during the acute phase and subsequently increased in the recovery phase. Antiretroviral therapy was given a month after the twice non-detections of SARS-CoV-2 to avoid immune reconstitution syndrome (IRIS). Previous reports suggest COVID-19 do not become more severe in untreated HIV patients than non-HIV patients. However, untreated HIV patients with COVID-19 should be followed up carefully for IRIS with ART. This article is protected by copyright. All rights reserved.
Keywords: Anti-retrovirus drug < Antiviral agents; Human immunodeficiency virus < Virus classification; SARS coronavirus < Virus classification.
. 2020 Jun 3.
doi: 10.1002/jmv.26102. Online ahead of print.
A Case of SARS-CoV-2 Infection in an Untreated HIV Patient in Tokyo, Japan
Takato Nakamoto[SUP] 1 [/SUP], Satoshi Kutsuna[SUP] 1 [/SUP], Yasuaki Yanagawa[SUP] 2 [/SUP], Kouhei Kanda[SUP] 1 [/SUP], Ayako Okuhama[SUP] 1 [/SUP], Yutaro Akiyama[SUP] 1 [/SUP], Yusuke Miyazato[SUP] 1 [/SUP], Satoshi Ide[SUP] 1 [/SUP], Keiji Nakamura[SUP] 1 [/SUP], Kei Yamamoto[SUP] 1 [/SUP], Norio Ohmagari[SUP] 1 [/SUP]
Affiliations
- PMID: 32492188
- DOI: 10.1002/jmv.26102
Abstract
We report a 28-year-old male co-infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; COVID-19) and human immunodeficiency virus (HIV). His clinical course of the COVID-19 pneumonia improved smoothly in 9 days; however, his immune status from HIV infection was not well-controlled due to a lack of antiretroviral therapy (ART). The HIV-1 viral load decreased during the acute phase and subsequently increased in the recovery phase. Antiretroviral therapy was given a month after the twice non-detections of SARS-CoV-2 to avoid immune reconstitution syndrome (IRIS). Previous reports suggest COVID-19 do not become more severe in untreated HIV patients than non-HIV patients. However, untreated HIV patients with COVID-19 should be followed up carefully for IRIS with ART. This article is protected by copyright. All rights reserved.
Keywords: Anti-retrovirus drug < Antiviral agents; Human immunodeficiency virus < Virus classification; SARS coronavirus < Virus classification.